Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Lefkowitz Steven W
   2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [CRMD] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Interim Chief Financial Ofcr
(Last)
(First)
(Middle)
C/O CORMEDIX INC., 745 ROUTE 202-206, SUITE 303		 3. Date of Earliest Transaction (Month/Day/Year)
01/10/2014
(Street)

BRIDGEWATER, NJ US 08807		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value per share               141,929 D  
Common Stock, $0.001 par value per share               100,000 I (1) Wade Capital Corporation Money Purchase Plan
Common Stock, $0.01 par value per share               1,000 I (1) Report Person's Wife

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $ 2.02 01/10/2014   A   200,000     (2) 01/09/2024 Common Stock, $0.001 par value per share 200,000 (2) 200,000 D  
Stock Option (right to buy) $ 2.02 01/10/2014   A   30,000     (7) 01/09/2024 Common Stock, $0.001 par value per share 30,000 (7) 30,000 D  
Swries C-3 Non-Voting Convertible Preferred Stock $ 1               (3)   (3) Common Stock, $0.001 par value per share 45,000   4,500 D  
Warrant (right to purchase Common Stock) $ 1.25             01/08/2015 01/08/2020 Common Stock, $0.001 par value per share 22,500   22,500 D  
Series C-3 Non-Voting Convertible Preferred Stock $ 1               (4)   (4) Common Stock, $0.001 par value per share 30,000   3,000 I (1) Wade Capital Corporation Money Purchase Plan
Warrant (right to purchase Common Stock) $ 1.25             01/08/2015 01/08/2020 Common Stock, $0.001 par value per share 15,000   15,000 I (1) Wade Capital Corporation Money Purchase Plan
Warrant (right to purchase Common Stock) $ 3.4375             08/20/2012 03/24/2015 Common Stock, $0.001 par value per share 5,000   5,000 D  
Stock Option (right to buy) $ 0.9               (5) 03/20/2023 Common Stock, $0.001 par value per share 120,000   120,000 D  
Stock Option (right to buy) $ 0.68               (6) 12/05/2022 Common Stock, $0.001 par value per share 150,000   150,000 D  
Warrant (right to purchase Common Stock) $ 0.4             11/13/2012 11/13/2017 Common Stock, $0.001 par value per share 37,500   37,500 D  
Warrant (right to purchase Common Stock) $ 0.4             09/20/2012 09/20/2017 Common Stock, $0.001 par value per share 87,500   87,500 I (1) Wade Capital Corporation Money Purchase Plan
Stock Option (right to buy) $ 0.29               (7) 01/06/2022 Common Stock, $0.001 par value per share 30,000   30,000 D  
Stock Option (right to buy) $ 1.1               (8) 08/11/2021 Common Stock, $0.001 par value per share 30,000   30,000 D  
Warrant (right to purchase Common Stock) $ 3.4375               (9) 03/24/2015 Common Stock, $0.001 par value per share 19,536   19,536 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Lefkowitz Steven W
C/O CORMEDIX INC.
745 ROUTE 202-206, SUITE 303
BRIDGEWATER, NJ US 08807		   X     Interim Chief Financial Ofcr  

Signatures

 Alexander M. Donalson by Power of Attorney   01/14/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
(2) The options vested 100% on January 10, 2014.
(3) On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
(4) On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
(5) These options vest quarterly over two years beginning June 13, 2013.
(6) These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
(7) The options vest in full on the first anniversary of the date of grant.
(8) The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
(9) The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of hte Company's registration statement related thereto.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.